DUBLIN--(BUSINESS WIRE)--The "Cell Line Development Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The cell line development service global market is expected to reach $1,702.2 million by 2028 growing at a double digit CAGR from 2020 to 2028.
Increasing demand for monoclonal antibodies, recombinant proteins and vaccines, growing incidence rate of oncology, autoimmune disorders, infectious diseases & genetic disorders and growth in research activities related to the diseases and also recombinant cell lines for the production recombinant biopharmaceutical proteins are driving the market.
Technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market. However, complexities in the development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market.
Furthermore, stringent and complex regulations and the high cost and technical requirement to adhere to accreditations such as GMP are posing threat to the industry.
Key Topics Covered:
1 Executive Summary
2 Market Dynamics
2.1 Drivers and Opportunities
2.1.1 Growing Incidence Rates of Oncology and Immunological Disorders and Increasing R&D Activities Related to the Diseases
2.1.2 Increasing Demand for Biologics and Biosimilars
2.1.3 Advanced Technologies for Screening, Cell Line Engineering and Bioprocessing
2.1.4 Increasing Number of Cros in APAC Regions
2.2 Restraints and Threats
2.2.1 Complexities in Development of Stable Cell Lines
2.2.2 High Risk of Contamination Due to Complex Purification Method
2.2.3 Stringent and Complex Regulations for Biologics in North America and Europe
2.2.4 High Cost and Technical Requirements to Obtain Gmp Certifications
3 Cell Line Development
3.1 Cell Line Construction
3.2 Host Cell Line Engineering
3.3 Expression System
3.4 Transient Gene Expression
3.5 Stable Cell Line Development
3.7 Upstream Process Development
4 Host Cell Lines
4.1 Cell Line Development Services Market, by Expression System
4.1.1 Microbial Expression Systems
4.1.2 Mammalian Expression System
4.1.3 Others (Insect and Plant Cell)
5 Cell Line Development Services, by Cell Type
5.3 Murine/Mouse Myeloma
5.4 Baby Hamster Kidney (Bhk) Cells
5.6 Human Embryonic Kidney (Hek) Cells
5.7 Human Embryonic Retinal Cells (Per.C6)
5.8 Others (E.Coli, Yeast, Insect Cell, Ht-1080, Hela Cell Line, Cap, Hkb-11, Huh-7)
6 Cell Line Development Services, by Applications
6.4 Cell Line Development Technologies
6.5 Cell Banking Services
6.6 Cell Line Characterization Services
7 Market Share Analysis
8 Key Developments
8.2 New Technology, Product and Service Launch
8.4 Other Developments
9 Company Profiles
9.1 Abzena plc
9.1.3 Service Portfolio
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.2 Albany Molecular Research, Inc.
9.3 AGC Inc.
9.4 Boehringer Ingelheim International GmbH
9.5 Catalent Inc.
9.6 Charles River Laboratories
9.7 Eurofins Scientific S.E.
9.8 Fujifilm Holdings Corporation
9.9 JSR Corporation
9.10 Lonza Group Ltd.
9.11 Rentschler Biopharma Se
9.12 Samsung Biologics Co. Ltd.
9.13 Sartorius Group
9.14 Thermofisher Scientific Inc.
9.15 Wuxi Biologics
- 3P Biopharmaceuticals
- A & G Pharmaceutical Inc ( Precision Antibody)
- AbSci, LLC
- AGC Inc. (AGC Biologics)
- Albany Molecular Research Inc.
- Anthem Biosciences Private Limited.
- Applied StemCell Inc.
- Batavia Biosciences B.V.
- BioFactura, Inc.
- Biologics International Corp.
- Boehringer Ingelheim International GmbH
- BPS Bioscience, Inc.
- Catalent Inc.
- Celonic AG (Glycotope GmbH)
- CEVEC Pharmaceuticals GmbH
- Charles River Laboratories International Inc.
- Cognate Bioservices Inc.
- Creative Diagnostics
- Cytovance Biologics
- Dyadic International, Inc.
- EirGenix, Inc.
- Eurofins Scientific S.E
- Fujifilm Holdings Corporation
- Fusion Antibodies
- Genscript Biotech Corporation
- GVK Biosciences Private Limited
- Horizon Discovery Ltd.
- JHL biotech Inc.
- JSR Corporation
- Kemwell Biopharma
- Lake Pharma Inc.
- LFB Biomanufacturing
- Lonza Group Ltd.
- Merck KGaA (BioReliance)
- Minapharm Pharmaceuticals
- NeuClone Pty. Ltd.
- PanGen Biotech Inc
- Polpharma Biologics S.A
- Precision Antibody
- Premas Biotech Pvt Ltd
- Proventus Bio
- Rentschler Biopharma SE
- Samsung Biologics Co. Ltd.
- Sartious Group
- Sino Biological Inc.
- Solentim Ltd.
- Syd labs
- Syngene International Ltd.
- The Antibody lab
- Thermofischer Scientific Inc.
- Trenzyme GmbH
- Wuxi Biologics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/gyjljt